Effects of dynorphin A(1-13) on opiate withdrawal in humans

Psychopharmacology

Volumn 137, Issue 4, 1998, Pages 326-332

  Specker, Sheila ^a   Wananukul, Winai ^b   Hatsukami, Dorothy ^a   Nolin, Kim ^a   Hooke, Lyn ^a   Kreek, Mary Jeanne ^c   Pentel, Paul R ^d  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c ROCKEFELLER UNIVERSITY   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Dynorphin; Human; Opiate withdrawal

Indexed keywords

DYNORPHIN[1-13]; OPIATE;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVOUSNESS; OPIATE ADDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SNEEZING; WITHDRAWAL SYNDROME;

ADULT; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYNORPHINS; EVOKED POTENTIALS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NARCOTICS; PEPTIDE FRAGMENTS; PROLACTIN; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0031745966     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050626     Document Type: Article

References (30)

1. Aceto MD, Dewey WL, Chang JK, Lee NM (1982) Dynorphin (1-13) effects in nontolerant and morphine-dependent rhesus monkeys. Eur J Pharmacol 83:139-142
2. Caudle RM, Isaac L (1987) Intrathecal dynorphin (1-13) results in irreversible loss of the tail flick reflex in rats. Brain Res 435: 1-6
3. Chiappa KH (ed) (1989) Evoked Potentials in clinical medicine, 2nd edn. Raven Press, New York, pp 593-608
4. Chou JZ, Pinto S, Kreek MJ, Chait BT (1993) Study of opioid peptides by laser desorption mass spectrometry. In: Harris LS (ed) Problems of drug dependence, 1992: Proceedings of the 54th Annual Scientific Meeting of the College on Problems of Drug Dependence, National Institute of Drug Abuse Research Monograph Series, Supt of Docs, US Govt Print Office, Washington, DC, DHHSO Pub No (ADM) 93-3505. 132:380
5. Chou JZ, Kreek MJ, Chait BT (1994) Matrix-assisted laserdescorption mass spectrometery of biotransformation products of dynorphin A in vitro. J Am Soc Mass Spectrom 5:10-16
6. 1-13 peptides in human blood, ex vivo. Peptides 17:983-990
7. Green PG, Lee NM (1988) Dynorphin A-(1-13) attenuates withdrawal in morphine-dependent rats: effect of route or administration. Eur J Pharmacol 145:67-272
8. Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA (1989) Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. Int J Pharmacol Exp Ther 250: 485-491
9. Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA (1990) Acute opioid physical dependence in humans: effect on naloxone at 6 and 24 hours post morphine. Pharmacol Biochem Behav 36: 393-399
10. Herman BH, Goldstein A (1985) Antinociception and paralysis induced by intrathecal dynorphin. J Pharmacol Exp Ther 232: 27-32
11. Hooke LP, He L, Lee NM (1995) Dynorphin A modulates acute and chronic opioid effects. J Pharmacol Exp Ther 273:292-297
12. Jasinski DR, Johnson RE, Kocher TR (1985) Clonidine in morphine withdrawal. Arch Gen Psychiatry 42:1063-1066
13. 2-dynorphin-(1-1.1) (kappa opioid agonists) in morphine (mu opioid agonist)-dependent rats. Life Sci 33 [Suppl I]: 559-562
14. Kreek MJ (1978) Medical complications in methadone patients. Ann NY Acad Sci 311:110-134
15. 1-13 administration causes elevation of serum levels of prolactin in human subjects. In: Harris LS (ed) Problems of drug dependence, 1993: proceedings of the 55th Annual Scientific Meeting of the College on Problems of Drug Dependence, National Institute of Drug Abuse Research Monograph Series, Supt of Docs, US Govt Print Office, Washington DC, NIH Pub No 94 3749, 141:108
16. Lee NM (1984) The role of dynorphin in narcotic tolerance mechanisms. NIDA Res Monogr 54: 162-167
17. Long JB, Petras JM, Mobley WC, Holaday JW (1988) Neurological dysfunction after intrathecal injection of dynorphin A(1-13) in the rat. II. Non opioid mechanisms mediate loss of motor, sensory and autonomic function. J Pharmacol Exp Ther 246: 1167-1174
18. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrin, phenmetrazine, and methylphenidate in men. Clin Pharmacol Ther 1:245-258
19. McNair D.M, Lorr M, Droppelman LF (1992) Profile of mood states (manual) (Revised edition). Education and Industrial Testing Service, San Diego
20. Pentel PR, Wananukul W, Hooke LP, Jones CRN, Hatsukami D, Anderson WR, Lee NM (1995) Effects of high intravenous doses of dynorphin A (1-13) on tail flick latency and central nervous system histology in rats. Pharmacol Biochem Behav 51:387-390
21. Shukla VK, Lemaire S (1994). Non-opioid effects of dynorphins: possible role of the NMDA receptor. Trends Pharmacol Sci 15:420-424
22. Takemori AE, Loh HH, Lee NM (1992) Suppression by dynorphin A-(1-13) of the expression of opiate withdrawal and tolerance in mice. Eur J Pharmacol 221:223-236
23. 1] dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependence mice. J Pharmacol Exp Ther 166:121-124
24. Tulunay FC, Fen MF, Chang JK, Loh HH, Lee NM (1981) Possible regulatory role of dynorphin on morphine-and endorphin-induced analgesia. J Pharmacol Exp Ther 219:296-298
25. Uneklabh T, Sintavanarong P, Wessagowit V, Lunkanapiochonchut L (1995) Clinical effect of dynorphin on heroin addicts. J Med Assoc Thai 78:509-516
26. Wang RIH, Wiesen RL, Lamid S, Roh BL (1974) Rating the presence and severity of opiate dependence. Clin Pharmacol Ther 16:653-658
27. Wen HL, Ho WKK (1982) Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur J Pharmacol 82:183-186
28. Wen HL, Ho WKK, Wen PYC (1984) Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur J Pharmacol 100:155-162
29. Yu J, Butelman ER, Woods JH, Chait BT, Kreek MJ (1996) In vitro biotransformation of dynorphin A(1-17) is similar in human and rhesus monkey blood as studied by matrix-assisted laser desorption/ionization mass spectrometry. J Pharmacol Exp Ther 279:507-514
30. Zhang S, Yu L (1995) Identification of dynorphins as endogenous ligands for an opioid receptor-like orphan receptor. J Biol Chem 270:22772-22776